Celcuity Inc. (CELC)
NASDAQ: CELC · Services-Medical Laboratories · Minneapolis, MN
Our rating: Cautious
Cautious reaffirmed at $66.79, moderate conviction, November 6, 2026.
Breaks if: The cautious view would be proved wrong if Celcuity's stock trades durably above $90 within the next 12 months on the back of a positive pivotal clinical readout or a licensing deal carrying an upfront payment of $200M or more from an established pharmaceutical partner — either event would demonstrate that the pipeline value embedded in the filings exceeds what a cautious read of the available figures supports.
Key figures
| Market value | $2.6B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$256M |
| Free cash flow, last 12 months | −$213M |
| Price to earnings | n/a |
| Free cash flow yield | −8.1% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −1192.9% |
| Beta to the S&P 500 | 1.12 |
| Volatility, annualized | 124.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-1.33 | −$66M |
| June 30, 2026 | n/a | n/a | $-1.44 | −$55M |
| March 31, 2026 | n/a | n/a | $-0.97 | −$55M |
| December 31, 2025 | n/a | n/a | $-0.98 | −$36M |
| September 30, 2025 | n/a | n/a | $-0.92 | −$45M |
| June 30, 2025 | n/a | n/a | $-1.04 | −$36M |
| March 31, 2025 | n/a | n/a | $-0.86 | −$36M |
| December 31, 2024 | n/a | n/a | $-0.87 | −$28M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 5%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 5%, Mistral 2%
23 ledger entries and 41 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.